NASDAQ:AXON - Axovant Sciences Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.27 -0.44 (-25.73 %)
(As of 12/10/2018 12:25 PM ET)
Previous Close$1.71
Today's Range$1.21 - $1.30
52-Week Range$1.02 - $6.59
Volume26,872 shs
Average Volume390,891 shs
Market Capitalization$209.10 million
P/E Ratio-0.63
Dividend YieldN/A
Beta0.42
Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in acquisition, development, and commercialization of therapeutics in the fields of neurology and psychiatry in the United States and the European Union. It focuses on developing AXO-Lenti-PD, an in vivo lentiviral gene therapy investigational product candidate for the one-time treatment of Parkinson's disease. The company is also developing nelotanserin, a selective 5-HT2A receptor inverse agonist, which is in Phase II clinical trial for the treatment of visual hallucinations in patients with Lewy body dementia (LBD) and REM sleep behavior disorder in patients with LBD. In addition, it focuses on developing RVT-104, a combination of rivastigmine and a peripheral muscarinic receptor antagonist as treatments for patients with Alzheimer's disease or DLB. The company was formerly known as Roivant Neurosciences Ltd. and changed its name to Axovant Sciences Ltd. in March 2015. The company was founded in 2014 and is based in London, the United Kingdom. Axovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.

Receive AXON News and Ratings via Email

Sign-up to receive the latest news and ratings for AXON and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AXON
Previous Symbol
CUSIPN/A
Phone44-20-3318-9708

Debt

Debt-to-Equity Ratio1.68
Current Ratio1.97
Quick Ratio1.97

Price-To-Earnings

Trailing P/E Ratio-0.63
Forward P/E Ratio-0.92
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.66 per share
Price / Book1.92

Profitability

EPS (Most Recent Fiscal Year)($2.06)
Net Income$-221,570,000.00
Net MarginsN/A
Return on Equity-302.21%
Return on Assets-119.21%

Miscellaneous

Employees45
Outstanding Shares122,280,000
Market Cap$209.10 million
OptionableOptionable

Axovant Sciences (NASDAQ:AXON) Frequently Asked Questions

What is Axovant Sciences' stock symbol?

Axovant Sciences trades on the NASDAQ under the ticker symbol "AXON."

How were Axovant Sciences' earnings last quarter?

Axovant Sciences Ltd (NASDAQ:AXON) announced its earnings results on Tuesday, August, 7th. The biotechnology company reported ($0.48) EPS for the quarter, missing the Zacks' consensus estimate of ($0.15) by $0.33. View Axovant Sciences' Earnings History.

When is Axovant Sciences' next earnings date?

Axovant Sciences is scheduled to release their next quarterly earnings announcement on Friday, February 8th 2019. View Earnings Estimates for Axovant Sciences.

What price target have analysts set for AXON?

5 brokers have issued 12-month target prices for Axovant Sciences' stock. Their forecasts range from $4.00 to $7.00. On average, they expect Axovant Sciences' stock price to reach $5.3333 in the next year. This suggests a possible upside of 319.9% from the stock's current price. View Analyst Price Targets for Axovant Sciences.

What is the consensus analysts' recommendation for Axovant Sciences?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axovant Sciences in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Axovant Sciences.

What are Wall Street analysts saying about Axovant Sciences stock?

Here are some recent quotes from research analysts about Axovant Sciences stock:
  • 1. According to Zacks Investment Research, "Axovant Sciences Ltd. is a biopharmaceutical company which focuses on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative disorders. Its product candidate includes RVT-101 which is in different clinical trial for the treatment of Alzheimer's disease and other forms of dementia. Axovant Sciences Ltd. is based in Hamilton, Bermuda. " (11/13/2018)
  • 2. HC Wainwright analysts commented, "Valuation and risks to the achievement of target price. Our price target of $7/share is based on an equally-weighted composite of: (a) $6.27/share, as a 35x multiple of taxed and diluted $2.30 discounted back to FY18 at 20% (in line with the expected PE multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $7.26/share (discounted cash flow analysis using a 15% discount rate and 2.0% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company)." (8/13/2018)
  • 3. Chardan Capital analysts commented, "We now assign an incremental $2/share of value to AXON based on AXON capturing some of this value. We expect Oxford BioMedica striking new partnerships in the GT space will provide further upside to shares from here. We note that Axovant has strengthened its management with the addition of gene therapy experts to its leadership. Axovant announced the addition of Dr. Michael Hayden as Chairman of its SAB. Dr. Hayden “played a key role in the discovery and development of Glybera”. With this deal, Axovant announced its new CTO will be Dr. Fraser Wright, the co-founder and former CTO of Spark Therapeutics (Buy)." (6/6/2018)

Has Axovant Sciences been receiving favorable news coverage?

Press coverage about AXON stock has been trending very positive on Monday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Axovant Sciences earned a news sentiment score of 3.9 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near future.

Who are some of Axovant Sciences' key competitors?

Who are Axovant Sciences' key executives?

Axovant Sciences' management team includes the folowing people:
  • Dr. Pavan Cheruvu M.D., CEO & Director (Age 36)
  • Dr. Gregory M. Weinhoff, Principal Financial & Accounting Officer (Age 47)
  • Mr. Mark Altmeyer, Pres & Chief Commercial Officer of Axovant Sciences GmbH (Age 57)
  • Dr. David T. Hung, Scientific Advisor of Group (Age 60)
  • Dr. Fraser Wright, Chief Technology Officer

When did Axovant Sciences IPO?

(AXON) raised $251 million in an initial public offering (IPO) on Thursday, June 11th 2015. The company issued 17,900,000 shares at a price of $13.00-$15.00 per share. Jefferies, Evercore ISI and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities and Baird were co-managers.

Who are Axovant Sciences' major shareholders?

Axovant Sciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (1.71%), BlackRock Inc. (1.17%), Connor Clark & Lunn Investment Management Ltd. (0.46%), Virtus ETF Advisers LLC (0.10%) and Marshall Wace North America L.P. (0.02%). Company insiders that own Axovant Sciences stock include David Hung, George Bickerstaff, Global Investors Lp Viking and W Anthony Vernon. View Institutional Ownership Trends for Axovant Sciences.

Which institutional investors are selling Axovant Sciences stock?

AXON stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P. and Virtus ETF Advisers LLC. View Insider Buying and Selling for Axovant Sciences.

Which institutional investors are buying Axovant Sciences stock?

AXON stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, BlackRock Inc. and Connor Clark & Lunn Investment Management Ltd.. Company insiders that have bought Axovant Sciences stock in the last two years include David Hung, George Bickerstaff, Global Investors Lp Viking and W Anthony Vernon. View Insider Buying and Selling for Axovant Sciences.

How do I buy shares of Axovant Sciences?

Shares of AXON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Axovant Sciences' stock price today?

One share of AXON stock can currently be purchased for approximately $1.27.

How big of a company is Axovant Sciences?

Axovant Sciences has a market capitalization of $209.10 million. The biotechnology company earns $-221,570,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis. Axovant Sciences employs 45 workers across the globe.

What is Axovant Sciences' official website?

The official website for Axovant Sciences is http://www.axovant.com.

How can I contact Axovant Sciences?

Axovant Sciences' mailing address is 20-22 BEDFORD ROW, LONDON X0, WC1R 4JS. The biotechnology company can be reached via phone at 44-20-3318-9708.


MarketBeat Community Rating for Axovant Sciences (NASDAQ AXON)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  291 (Vote Outperform)
Underperform Votes:  305 (Vote Underperform)
Total Votes:  596
MarketBeat's community ratings are surveys of what our community members think about Axovant Sciences and other stocks. Vote "Outperform" if you believe AXON will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXON will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel